235 related articles for article (PubMed ID: 34027867)
1. Predictive Significance of Ki-67 and Platelet Lymphocyte Ratio in Patients with Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy.
Yilmaz H; Demirag G; Sullu Y; Yilmaz A
J Coll Physicians Surg Pak; 2021 May; 31(5):546-552. PubMed ID: 34027867
[TBL] [Abstract][Full Text] [Related]
2. The ratio of hemoglobin to red cell distribution width predicts survival in patients with gastric cancer treated by neoadjuvant FLOT: a retrospective study.
Yılmaz A; Mirili C; Tekin SB; Bilici M
Ir J Med Sci; 2020 Feb; 189(1):91-102. PubMed ID: 31832860
[TBL] [Abstract][Full Text] [Related]
3. Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT.
McNamee N; Nindra U; Shahnam A; Yoon R; Asghari R; Ng W; Karikios D; Wong M
J Gastrointest Oncol; 2023 Apr; 14(2):494-503. PubMed ID: 37201072
[TBL] [Abstract][Full Text] [Related]
4. Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer.
Monti M; Prochowski Iamurri A; Bianchini D; Gallio C; Esposito L; Montanari D; Ruscelli S; Molinari C; Foca F; Passardi A; Vittimberga G; Morgagni P; Frassineti GL
Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630794
[TBL] [Abstract][Full Text] [Related]
5. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience.
Tastekin D; Paksoy N; Dogan I; Ferhatoglu F; Khanmammadov N; Bozbey HU; Karabulut S
J Cancer Res Ther; 2023; 19(2):253-258. PubMed ID: 37006064
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
Jia W; Yuan L; Ni H; Xu B; Zhao P
Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
[TBL] [Abstract][Full Text] [Related]
8. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
[TBL] [Abstract][Full Text] [Related]
9. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Möhring C; Timotheou A; Mańczak A; Sadeghlar F; Zhou T; Mahn R; Bartels A; Monin M; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Giordano FA; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
J Cancer Res Clin Oncol; 2023 May; 149(5):1849-1862. PubMed ID: 35763109
[TBL] [Abstract][Full Text] [Related]
11. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
12. Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer.
Tomás TC; Eiriz I; Vitorino M; Vicente R; Gramaça J; Oliveira AG; Luz P; Baleiras M; Spencer AS; Costa LL; Liu P; Mendonça J; Dinis M; Padrão T; Correia M; Atalaia G; Silva M; Fiúza T
World J Gastrointest Oncol; 2022 Jul; 14(7):1307-1323. PubMed ID: 36051098
[TBL] [Abstract][Full Text] [Related]
13. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
[TBL] [Abstract][Full Text] [Related]
14. After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients.
Gong W; Zhao L; Dong Z; Dou Y; Liu Y; Ma C; Qu X
J Clin Lab Anal; 2018 Jun; 32(5):e22364. PubMed ID: 29251364
[TBL] [Abstract][Full Text] [Related]
15. Controlling Nutritional Status (CONUT) Score Is a Prognostic Factor for Patients with Gastric Cancer Treated by Perioperative FLOT.
Akagunduz B; Demir M; Atcı MM
J Gastrointest Cancer; 2022 Sep; 53(3):571-580. PubMed ID: 34263428
[TBL] [Abstract][Full Text] [Related]
16. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
18. Systemic inflammatory response markers for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer.
Skórzewska M; Pikuła A; Gęca K; Mlak R; Rawicz-Pruszyński K; Sędłak K; Paśnik I; Polkowski WP
Cytokine; 2023 Dec; 172():156389. PubMed ID: 37852156
[TBL] [Abstract][Full Text] [Related]
19. Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study.
Rinninella E; Strippoli A; Cintoni M; Raoul P; Vivolo R; Di Salvatore M; Genco E; Manfredi R; Bria E; Tortora G; Gasbarrini A; Pozzo C; Mele MC
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33809587
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
